关键信息
-
基因名
Integrin alpha V beta 3
- 应用
-
别名
CD51; ITG-AV; MSK8; VNRA; Vitronectin Receptor,Alpha Polypeptide
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P06756
-
表达区间
Phe31~Gly560
-
分子量
62kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Integrin alpha V beta 3 is a critical transmembrane protein that plays a fundamental role in cellular adhesion and signaling processes. It is primarily expressed on the surface of various cell types, including endothelial cells and osteoclasts, and is involved in numerous physiological functions such as wound healing, angiogenesis, and bone remodeling. Aberrant expression of alpha V beta 3 integrin has been implicated in several pathological conditions, particularly in tumor progression and metastasis, making it a significant target for cancer therapies. Research has focused on the molecular structure and functional mechanisms of this integrin to understand its role in tumor microenvironments. The development of recombinant alpha V beta 3 proteins has enabled scientists to study its interactions with extracellular matrix components and signaling pathways in more detail. Furthermore, these recombinant proteins have been utilized to design integrin inhibitors that can potentially block tumor cell adhesion and migration, thus providing a novel approach for cancer treatment. The exploration of integrin alpha V beta 3 continues to be a promising area of biomedical research, contributing to advances in targeted therapy and improved clinical outcomes for patients facing integrin-related diseases.
